{"id":"NCT00189306","sponsor":"Graceway Pharmaceuticals, LLC","briefTitle":"Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream","officialTitle":"An Open-label Study to Evaluate the Safety and Long-Term Clinical Efficacy of Imiquimod 5% Cream Applied Once Daily 7 Days Per Week for 6 Weeks in the Treatment of Superficial Basal Cell Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-03","primaryCompletion":"2007-04","completion":"2007-04","firstPosted":"2005-09-19","resultsPosted":"2008-11-26","lastUpdate":"2010-08-10"},"enrollment":169,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Superficial Basal Cell Carcinoma"],"interventions":[{"type":"DRUG","name":"Imiquimod 5% cream","otherNames":["Aldara (imiquimod) 5% cream - 250 mg / packet"]}],"arms":[{"label":"Aldara","type":"EXPERIMENTAL"}],"summary":"An open-label study to evaluate the safety and the ability of Imiquimod 5% cream, applied topically, to clear superficial basal cell carcinoma and to keep it clear for 5 years of follow-up.","primaryOutcome":{"measure":"Number of Participants With Sustained Clearance Rate of Superficial Basal Cell Carcinoma (sBCC)","timeFrame":"5 years","effectByArm":[{"arm":"Aldara","deltaMin":119,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":18,"countries":["Australia","New Zealand"]},"refs":{"pmids":["17034468","20666194"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":169},"commonTop":["Application site reaction","Headache","Pain","Rhinitis"]}}